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Abstract 
Against a backdrop of rising antibiotic resistance and a dwindling pipeline of new 
antibacterial drugs, this thesis set out to examine the potential of bacteriophage (phage) 
therapy as an alternative or complementary means of treating bacterial infection. Phage 
therapy is used as a frontline antibacterial therapy in the former Soviet bloc countries but 
remains an unexplored technology in Western science. To investigate the reasons behind 
this and other aspects of phage therapy, this thesis undertook the development of 
bacteriophage-based products against two important human bacterial pathogens, 
methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Pseudomonas 
aeruginosa (MRPA). 
 
To develop phage products in today’s scientific and regulatory framework it was necessary 
to return to basic principles. The first stage in this process involved the assembly of 
reference collections of the target bacteria. Once these were available, bacteriophages were 
isolated from a range of environmental sources, and their spectrum of activity and physical 
characteristics evaluated. Bacteriophages with the appropriate reactivity profile were then 
tested for stability, morphology, and further analysed using molecular biological 
techniques. Phages with therapeutic potential were then combined into mixtures or 
“cocktails” and their activity evaluated against clinical isolates from different geographical 
regions. Lastly, a commercial phage product was used in one compassionate case study 
involving a hospital patient to treat a refractory P. aeruginosa urinary tract infection. 
  
Fifty-two MRPA and fifty-eight MRSA phages were isolated over a period of 18 months. 
Selected phage therapeutic candidates were shown to be physically stable and genetically 
different from each other. They also showed a broad spectrum of activity against the 
targeted pathogens and this resulted in the production of three prototypes cocktails for each 
target pathogen. The MRPA cocktails achieved a reactivity of 62%-90% against clinical 
isolates from four geographical areas while the MRSA cocktails achieved a reactivity of 
61%-96% in two geographical areas. In the clinic, a compassionate phage therapy treatment 
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was well tolerated, produced no adverse side-effects, and in combination with antibiotics, 
resulted in the complete eradication of a refractory P. aeruginosa urinary tract infection.   
 
This thesis has demonstrated, for the first time in Australia, that it is possible to develop 
stable, fully characterised, broad-spectrum bacteriophage-based products with the potential 
to treat human infections caused by MRSA and MRPA. It also showed the value of phage 
therapy in the clinic by eradicating a chronic P. aeruginosa infection. Furthermore, though 
not presented in the main body of this thesis, two of the bacteriophage prototypes 
developed here (one MRSA and one MRPA) were recently shown to be effective in treating 
bacterial infections in two separate animal models.  
 
Phage therapy has the potential to play a major role in addressing the serious problems 
caused by the ever-widening antibiotic resistance crisis. No doubt, there will be production 
and regulatory hurdles to overcome and an urgent requirement to train a new generation of 
microbiologists and clinicians skilled at developing and administering these powerful 
antibacterials. However, it is now obvious that the old paradigm of depending on a constant 
stream of novel antibiotics is no longer valid and alternative technologies such as this must 
be fully explored. 
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